PLA2R1 and infection: Mini-dose rituximab may be more suitable for the “vulnerable” subset of the PMN population (such as the elderly, patients susceptible to infection, those who have newly recovered from a severe infection, or patients with very low serum immunoglobulin, and low anti-PLA2R antibody titer).